APR 06, 2016 07:30 AM PDT

Keynote Speaker: Recent Progress in Predictive Biomarker Testing in Oncology

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Director of Molecular Pathology, Carolinas Pathology Group
    Biography
      After completing his undergraduate work in Applied Biology at Georgia Tech, John received his Ph.D. in Medical Genetics from the University of Alabama at Birmingham and his Doctorate in Medical Genetics at the Greenwood Genetic Center.
      Since 2001 he has worked with the Carolinas Pathology Group as Director of Molecular Pathology for the Carolinas Laboratory Network. His primary responsibility is supervision of the Molecular Pathology Laboratory which provides state of the art molecular testing services for the hospitals and facilities within the Carolinas HealthCare system.
      Dr Longshore is a diplomate of the American Board of Medical Genetics in Clinical Molecular Genetics and an active member of the American College of Medical Genetics, the American Society of Human Genetics and the Association for Molecular Pathology. Away from his professional life, John enjoys fly fishing, swimming, travel and spending time with his wife and children.

    Abstract:

    Recent advances in personalized medicine and associated companion diagnostic therapeutics have led to an increased utilization of genetic markers in oncology therapy selection.  The rapid acceleration of biomarker driven therapy has been widely accepted into clinical guidelines based upon proven clinical utility and unprecedented patient outcomes.  During this presentation, a discussion of processes used for tissue acquisition and processing, pre-analytics, biomarker testing, and result reporting will be presented.  A special emphasis will be given to the discussing the power and pitfalls of common biomarker testing techniques such as real-time PCR companion diagnostic testing, immunohistochemistry, FISH, and next-generation sequencing panels. The goal of this presentation is to help improve the oncology patient journey by increasing access to high quality biomarker testing.

    Learing Objectives:

    • To understand the fundamentals of personalized medicine and companion diagnostics
    • To review current therapeutic products associated with companion and complementary diagnostics
    • To gain an understanding of the future of personalized medicine in oncology

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...